Evidence map›Paper›PMID 36902668›Full record

ReviewJournal of clinical medicine2023

Type 2 Diabetes Prevention Programs-From Proof-of-Concept Trials to National Intervention and Beyond.

Jaakko Tuomilehto, Matti Uusitupa, Edward W Gregg, Jaana Lindström

Full text readReview
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Building diabetes prevention and remission programs across Canada: learning from England.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jaakko TuomilehtoPopulation Health Unit, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00271 Helsinki, Finland.ORCID 0000-0002-3424-0745
Matti UusitupaInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, 70210 Kuopio, Finland.ORCID 0000-0001-6052-2001
Edward W GreggSchool of Population Health, Royal College of Surgeons of Ireland, University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.
Jaana LindströmPopulation Health Unit, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00271 Helsinki, Finland.ORCID 0000-0001-9255-020X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevention of type 2 diabetes (T2D) in high-risk people with lifestyle interventions has been demonstrated by several randomized controlled trials. The intervention effect has sustained up to 20 years in post-trial monitoring of T2D incidence. In 2000, Finland launched the national T2D prevention plan. For screening for high T2D risk, the non-laboratory Finnish Diabetes Risk Score was developed and widely used, also in other countries. The incidence of drug-treated T2D has decreased steadily since 2010. The US congress authorized public funding for a national diabetes prevention program (NDPP) in 2010. It was built around a 16-visit program that relies on referral from primary care and self-referral of persons with either prediabetes or by a diabetes risk test. The program uses a train-the-trainer program. In 2015 the program started the inclusion of online programs. There has been limited implementation of nationwide T2D prevention programs in other countries. Despite the convincing results from RCTs in China and India, no translation to the national level was introduced there. T2D prevention efforts in low-and middle-income countries are still limited, but results have been promising. Barriers to efficient interventions are greater in these countries than in high-income countries, where many barriers also exist. Health disparities by socioeconomic status exist for T2D and its risk factors and form a challenge for preventive interventions. It seems that a stronger commitment to T2D prevention is needed, such as the successful WHO Framework Convention on Tobacco Control, which legally binds the countries to act.

Indexed as

diabetes preventionimpaired glucose tolerancenational implementationproof-of-concept trials

Identifiers

PMID36902668
PMCPMC10003211

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read49
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.